Zenith Drugs Limited
₹78.45
-5.77%
Delayed · cached 15 min
Fair value analysis
ZENITHDRUG
Zenith Drugs Limited
₹46.35
Close used for this calculation
₹97.88Fair value
Financial DNA Score
Profitability · Returns · Balance Sheet · Efficiency · Growth
58/100
Quality radar
Consensus fair value
₹97.88
Below FV▲ +111.2% against the close used
Model range ₹69.70 – ₹199.56
The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.
Price target range & 52-week position
Bear₹69.70Fair value₹97.88Bull₹199.56
FairClose
52-week traded range
52W low ₹35.2052W high ₹69.85
The 52-week range is measured from the stored price history, not estimated.
Valuation summary
Trading below the consensus fair value
Zenith Drugs Limited closed at ₹46.35, 52.6% below the consensus fair value of ₹97.88 drawn from 7 valuation models.
Financial DNA score 58/100 — Good. P/E of 7.8x against the 20x sector multiple the P/E model uses.
Quantitative summary only — not investment advice.
All valuation models
DCF Valuation
₹104.77
+126.0%
Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10
g=8%, r=10%, tg=3%, n=10yr
Graham Number
₹69.70
+50.4%
√(22.5 × EPS × BVPS)
EPS=5.59, BVPS=38.63
P/E Fair Value
₹199.56
+330.6%
EPS × 35.7x (sector P/E)
EPS=5.59, Sector P/E=35.7x
EV/EBITDA
₹87.61
+89.0%
(EBITDA × 10x − Net Debt) ÷ Shares
EBITDA=180M
Book Value (P/B)
₹128.57
+177.4%
BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]
BVPS=38.63, ROE=26.3%, g=3%, r=10%
Reverse DCF
₹46.35
+0.0%
Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV
Implied: -5% | Historical: 0%
Margin of Safety
₹93.51
+101.7%
Avg(DCF, Graham, P/E) × 75% (25% safety buffer)
Avg fair value=124.68, MoS=25%
Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.
Educational data only. Not a recommendation to buy, sell or hold any security.